Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder by Balogh, Emese et al.
Balogh et al. Arthritis Research & Therapy 2013, 15:R221
http://arthritis-research.com/content/15/6/R221RESEARCH ARTICLE Open AccessComparison of remission criteria in a tumour
necrosis factor inhibitor treated rheumatoid
arthritis longitudinal cohort: patient global health
is a confounder
Emese Balogh1,2, Joao Madruga Dias1, Carl Orr1, Ronan Mullan1, Len Harty1, Oliver FitzGerald1, Phil Gallagher1,
Miriam Molloy1, Eileen O’Flynn1, Alexia Kelly1, Patricia Minnock1, Madeline O’Neill1, Louise Moore1,
Mairead Murray1, Ursula Fearon1 and Douglas J Veale1*Abstract
Introduction: Our objectives were to assess the frequency and sustainability of American College of Rheumatology
(ACR)/European League against Rheumatism (EULAR) and Disease Activity Score (DAS)28(4v)–C-reactive protein
(CRP) remission 12 months after the initiation of tumour necrosis factor inhibitor (TNFi) therapy in a rheumatoid
arthritis (RA) cohort.
Methods: Data were collected of 273 biologic naive RA patients at baseline, then 3, 6 and 12 months post-TNFi
therapy. Remission status was calculated using DAS28(4v)-CRP <2.6 and ACR/EULAR Boolean criteria. Response was
scored using EULAR criteria.
Results: Mean (range) patient age was 59.9 (7.2-85.4) years with disease duration of 13.4 (1.0-52.0) years. Responder
status maintained from 3–12 months (86%, 82.4%), laboratory/clinical parameters (erythrocyte sedimentation rate
(ESR), CRP, patient global health (PGH), DAS28(4v)-CRP) also showed sustained improvement (P < 0.05). DAS28
remission was reached by 102 subjects at 1 year, 27 patients were in Boolean remission, but 75 missed it from the
DAS28 remission group. Patients in remission were younger (P = 0.041) with lower baseline tender joint count (TJC)
28 and PGH than those not in remission (P = 0.001, P = 0.047). DAS28 remission patients were older (P = 0.026) with
higher 12 months PGH and subsequently higher DAS28 than Boolean remission patients (P < 0.0001). Patients not
achieving Boolean remission due to missing one subcriteria most frequently missed PGH ≤1 criteria (79.8%).
Conclusions: Only 10% of this TNFi treated cohort achieved remission according to the new ACR/EULAR criteria,
which requires lower disease activity. More stringent criteria may ensure further resolution of disease activity and
better longterm radiographic outcome, which supports earlier intervention with biologic therapy in RA.Introduction
Early diagnosis and rapid initiation of treatment has
become the mission in rheumatoid arthritis (RA).
Several composite indices are used for measuring
disease activity, response and remission. The disease activ-
ity score based on 28-joint count (DAS28) is a validated
method of outcome measures in clinical trials and clinical* Correspondence: douglas.veale@ucd.ie
1Dublin Academic Medical Centre, Department of Rheumatology,
St. Vincent’s University Hospital, Elm Park, Dublin 4, Ireland
Full list of author information is available at the end of the article
© 2013 Balogh et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orpractice [1]. The DAS28 score, European League Against
Rheumatism (EULAR) response criteria, and low disease
activity criteria were developed originally using the ery-
throcyte sedimentation rate (ESR) as an element of the
four-variable score (DAS28(4v)-ESR) [2,3]. Later find-
ings highlighted the importance of C-reactive protein
(CRP) – being an acute-phase reactant, it might give
better estimation of short-term changes in disease ac-
tivity – and therefore CRP was used in disease assessment
as a useful outcome measure in the four-variable DAS28
including CRP (DAS28(4v)-CRP) [4].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and the most widely used in clinical practice. DAS28-CRP
gives a good estimation of DAS28-ESR on a group level
[5]. Further recommendations were made on the applica-
tion of DAS28(4v)-CRP, setting similar cutoff values to the
DAS28(4v)-ESR for definitions of disease remission as well
as low, moderate or high disease activity [6]. Originally,
the remission threshold was set to DAS28(4v)-CRP <2.6,
equal to DAS28(4v)-ESR, although some earlier results
suggest that DAS-28(4v)-CRP levels and their cutoff
values for remission or response are lower [2,6,7]. At pre-
sent, DAS28 criteria are widely used in formulas either
with the ESR or CRP.
More effective drugs and treatment strategies allowed
remission to become the treatment target in RA, al-
though even in remission patients can experience radio-
graphic progression [8-10]. Limitations of the previous
remission criteria and the ultimate goal of treating to
remission urged the collaboration to establish a new
composite tool for measuring remission in RA. New
RA remission criteria were developed by the American
College of Rheumatology (ACR)/EULAR in 2011 on the
basis of using data from four clinical trials and need to
be validated using different datasets in clinical practice
[11]. To be classified as in remission according to these
criteria, patients must have swollen joint count out of 28
joints (SJC28), tender joint count out of 28 joints
(TJC28), CRP (mg/dl) and patient global health assess-
ment (PGH) on a 0 to 10 visual analogue scale of 1 or
less [11].
Previous findings showed that, despite minimal disease
activity, patients might not fulfil the ACR/EULAR remis-
sion criteria, mainly because these RA patients regularly
do not meet the PGH criterion of the provisional ACR/
EULAR Boolean-based definition despite a good clinical
disease state [12]. Prince and colleagues compared the
performance of ACR/EULAR Boolean and Simplified
Disease Activity Index (SDAI) remission criteria with
DAS28(4v)-ESR criteria and DAS28(4v)-CRP <2.6 or <2.3
criteria [7]. They suggested that overall just a small por-
tion of patients reached and remained in remission in the
long term, and fewer patients reached ACR/EULAR re-
mission than any DAS28 remission [7]. The objective of
this study was to examine the performance of the ACR/
EULAR Boolean and the DAS28(4v)-CRP remission status
in a routine clinical setting involving biologic-treated RA
patients.
Methods
Patient recruitment
Demographic, clinical and laboratory data of a RA co-
hort (n = 273), prior to commencing tumour necrosis
factor-alpha inhibitor (TNFi) therapy, were collected in
the Distiller database at routine clinics in Dublin. Alldata collection was compliant with the Helsinki declar-
ation and good clinical practise; ethical approval was not
required by the St. Vincent’s University Hospital Research
Ethics committee. All patients have been diagnosed with
RA according to the 1987 classification criteria and were
due to start biological treatment for persistent disease ac-
tivity; no consent was needed [13]. Data were collected at
four timepoints: at baseline (0), and then 3, 6 and 12
months after initiating TNFi therapy.
Data collection
Demographic data included patient age, sex and disease
duration (years). The following clinical and laboratory
parameters have also been recorded at all timepoints:
TJC28, SJC28, PGH on a 0 to 10 visual analogue scale,
levels of CRP, ESR and DAS28(4v)-CRP. We did not
stratify patients by therapy, and nor did we stage by
Steinbrocker functional class.
Scoring response, low disease activity and remission
Response to treatment was scored with EULAR response
criteria in three categories: good response, moderate re-
sponse, and nonresponse [14]. Remission status was cal-
culated using both DAS28(4v)-CRP remission criteria
and ACR/EULAR Boolean criteria [11-15]. Patients with
DAS28(4v)-CRP <2.6 fulfilled DAS28 remission. ACR/
EULAR Boolean remission was defined by the follow-
ing: TJC28 ≤1, SJC28 ≤1, PGH ≤1, and CRP (mg/dl) ≤1.
Low disease activity was defined by 2.6 ≤DAS28(4v)-
CRP ≤3.2 [6,14,16].
Statistical analysis
Statistical analysis of nonparametric variables was per-
formed with SPSS software (v20). Comparison of DAS28
(4v)-CRP and DAS28(4v)-ESR remission criteria was per-
formed using the κ formula with the interpretation of
Landis and Koch for κ values, where <0 indicates no
agreement, 0 to 0.2 slight, 0.21 to 0.40 fair, 0.41 to 0.60
moderate, 0.61 to 0.80 substantial, and 0.81 to 1.0 almost
perfect agreement [5]. Improvement of clinical and labora-
tory data (TJC28, SJC28, PGH, CRP, ESR) was analysed by
the Wilcoxon signed-rank test. Baseline data are presented
as mean ± standard deviation or percentages (%) cal-
culated by the chi-square test. The Mann–Whitney U
test was applied for calculations between independent
nonparametric variables. All P values are two-sided and
P <0.05 was considered statistically significant.
Results
Demographic data
Mean (range) patient age was 59.9 (7.2 to 85.4) with
mean (range) disease duration of 13.4 (1.0 to 52.0) years,
and mean ± standard deviation DAS28(4v)-CRP score of
5.33 ± 1.07. The female:male ratio was 3:1, and 70.2% of
Table 1 Baseline demographic and clinical data of rheumatoid arthritis patients in different 12-month
remission statuses
Whole cohort
(n = 273)
DAS28 remission
(n = 102)
Only DAS28
remission (n = 75)
DAS28 + Boolean
remission (n = 27)
Not in any
remission (n = 171)
Age (years) 59.89 (7 to 85) 57.12 (7 to 85) 59.17 (26 to 85) 51.43 (7 to 75) 61.53 (30 to 86)
Disease duration (years) 13.43 (1 to 52) 11.1 (1 to 40) 12,23 (1 to 40) 7.91 (1 to 21) 14.68 (1 to 52)
Female (%) 74.7 68.6 66.7 74.1 78.4
RF positivity (%) 70.2 69.7 71.2 65.4 70.5
Anti-CCP positivity (%) 75.2 69.4 65.7 78.6 79.7
DAS28(4v)-CRP 5.33 ± 1.07 5.15 ± 1.1 5.18 ± 1.16 5.08 ± 0.9 5.44 ± 1.05
TJC28 10.24 ± 6.86 8.71 ± 6.83 9.19 ± 7.34 7.37 ± 5.05 11.15 ± 6.73
SJC28 9.86 ± 6.20 9.6 ± 6.25 9.73 ± 6.57 9.22 ± 5.36 10.02 ± 6.19
CRP (mg/dl) 2.76 ± 2.93 3.16 ± 3.14 3.23 ± 3.12 2.93 ± 3.26 2.53 ± 2.78
PGH 5.92 ± 2.28 5.6 ± 2.29 5.57 ± 2.33 5.68 ± 2.22 6.12 ± 2.26
Data presented as mean (range), mean ± standard deviation or percentage. DAS28, disease activity score based on 28-joint count; RF, rheumatoid factor; anti-CCP,
anti-cyclic-citrullinated peptide antibody; DAS28(4v)-CRP, disease activity score based on 28-joint count, C-reactive protein and patient global health; TJC28, tender
joint count out of 28 joints; SJC28, swollen joint count out of 28 joints; CRP, C-reactive protein; PGH, patient global health.
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anti-cyclic citrullinated peptide positive. Baseline demo-
graphics are detailed in Table 1. At baseline none of the
patients were in Boolean or DAS28 remission and due
to their high disease activity anti-TNF treatment was
commenced.
Applying DAS28(4v)-CRP and DAS28(4v)-ESR remission
criteria to the cohort (remission <2.6)
We compared remission and response rates at different
timepoints with these two criteria and found at least
moderate agreement between the two groups at any
timepoint (κ value >0.556, P <0.0001 at any timepoint);
hence we decided to perform further calculations with
the DAS28(4v)-CRP formula (Table 2).
Patients in remission
There was no significant difference between the num-
ber of patients achieving remission with DAS28(4v)
or three-variable disease activity score based on 28 swollen
and tender joint count, and C-reactive protein (DAS(3v))Table 2 Agreement of remission and response rates
calculated with DAS28(4v)-ESR and DAS28(4v)-CRP at
different timepoints after initiating biological therapy
κ value
Remission – 3 months 0.689 (P <0.0001)
Remission – 6 months 0.617 (P <0.0001)
Remission – 12 months 0.717 (P <0.0001)
Response – 3 months 0.556 (P <0.0001)
Response – 6 months 0.731 (P <0.0001)
Response – 12 months 0.725 (P <0.0001)
κ value according to Landis and Koch interpretation. DAS28(4v)-ESR, disease
activity score based on 28-joint count, erythrocyte sedimentation rate and
patient global health, DAS28(4v)-CRP, disease activity score based on 28-joint
count, C-reactive protein and patient global health.criteria (n = 102 vs. n = 115) in this cohort at 1 year, so we
made further calculations with DAS28(4v).
All ACR/EULAR Boolean remission patients were in
DAS28 remission at all timepoints. Baseline demogra-
phic and clinical data for remission groups are presented
in Table 1, and 1-year remission demographic and clini-
cal data are presented in Table 3.
From the cohort of 273 patients, 102 subjects (37%)
were in DAS28 remission, 75 (27%) patients were in
DAS28 remission alone and 27 (10%) were in both
DAS-28 and Boolean remission at 12 months. Boolean
and DAS28 remission rates were compared with no-
remission. Patients in DAS28 remission were signifi-
cantly younger (P = 0.041) and had lower baseline TJC28
and PGH scores than their nonremission counterparts
(P = 0.001, P = 0.047). They also had significantly lower
12-month disease activity (TJC28, SJC28, CRP, PGH,
DAS28(4v)-CRP: all P <0.0001) (Tables 1 and 3). Boolean
remission patients were younger (P = 0.003) with lower
baseline TJC28 (P = 0.028) and 12-month disease activity
(TJC28, SJC28, CRP, DAS28(4v)-CRP: all P <0.025) than
nonremission patients (Tables 1 and 3).
Significantly fewer patients reached Boolean remission
than DAS28 remission (P <0.0001) (Figure 1A) at all
timepoints, and therefore we investigated the reasons for
differences in disease activity with comparing Boolean
remission group versus the part of DAS28 remission
group who missed ACR/EULAR remission (only DAS28
remission group). We found that Boolean remission pa-
tients were younger (P = 0.026) and had lower 12-month
DAS28(4v)-CRP and PGH values than only DAS28 re-
mission patients (both P <0.0001) (Tables 1 and 3).
The maximum level of disease activity for a Boolean
remission patient in our cohort was 2.52 calculated
by DAS28. Because Boolean criteria do not allow such
variability in the subcriteria scores as does DAS28, at
Table 3 Twelve-month demographic and clinical data of rheumatoid arthritis patients in different remission statuses
DAS28 remission
(n = 102)
Only DAS28
remission (n = 75)
DAS28 + Boolean
remission (n = 27)
Not in any
remission (n = 171)
DAS28(4v)-CRP 1.99 ± 0.31 2.08 ± 0.28 1.75 ± 0.27 3.97 ± 1.12
TJC28 0.17 ± 0.45 0.17 ± 0.48 0.15 ± 0.36 4.92 ± 5.39
SJC28 0.41 ± 1.17 0.53 ± 1.34 0.07 ± 0.27 4.05 ± 4.66
CRP (mg/dl) 0.53 ± 0.61 0.56 ± 0.71 0.43 ± 0.14 1.28 ± 2.84
PGH 2.08 ± 1.56 2.58 ± 1.52 0.7 ± 0.46 4.99 ± 2.39
Low disease activity (%) 100 100 100 28.1
Responder (%) 100 100 100 71.9
Good response (%) 94.1 92 100 24.6
Moderate response (%) 5.9 8 0 47.4
Nonresponse (%) 0 0 0 28.1
Data presented as mean ± standard deviation or percentage. DAS28, disease activity score based on 28-joint count; DAS28(4v)-CRP, disease activity score based on
28-joint count, C-reactive protein and patient global health; TJC28, tender joint count out of 28 joints; SJC28, swollen joint count out of 28 joints; CRP, C-reactive
protein; PGH, patient global health.
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Figure 1 Characteristics of disease activity score based on 28 joints and Boolean remission groups. (A) Percentage of patients in disease
activity score based on 28 joints (DAS28) remission versus Boolean remission. 3 m, 6 m and 12 m: 3 months, 6 months and 12 months post
tumour necrosis factor inhibitor therapy. (B) The 1-year four-variable disease activity score (DAS28(4v)) was higher for patients who failed Boolean
remission due to just one subcriterion being ≤1, but disease activity did not differ from Boolean remission calculated with the three-variable
formula (DAS28(3v)). This explains that significant differences in disease activity resulted mainly in higher patient global health. (C) The DAS28(4v)
was higher in the only DAS28 remission group, but disease activity did not differ from Boolean remission patients calculating with the DAS28(3v).
This explains that significant differences in disease activity resulted mainly in higher patient global health. ***P <0.0001. SD, standard deviation.
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due to the originally more stringent disease activity
criteria. These data suggest that Boolean remission
criteria are originally stricter in defining remission
than the DAS28 criteria. In view of the latter, Boolean
remission patients are more likely to be better res-
ponders for biological therapy than DAS28 remission
patients.Patient global health as a limiting factor of Boolean
remission status
We identified patients who fulfil most Boolean remission
criteria with the exception of one variable (n = 84) and
concluded that higher PGH has a greater impact on
remission status than other variables, with an effect to-
wards nonremission. Even though there were three re-
mission criteria fulfilled, 67 patients (80%) did not reach
remission due to residual disease activity of PGH >1,
another eight patients (9%) due to SJC >1, four patients
(5%) due to TJC >1 and five patients (6%) due to CRP >1.
These results are in concordance with the findings of
Studenic and colleagues in 2012 about the limiting charac-
teristics of PGH [17].
For those patients missing Boolean remission failing just
one subcriterion at 1 year (n = 84), 12-month DAS28(4v)-
CRP scores were higher (P <0.0001) than scores of pa-
tients reaching Boolean remission. Although 12-month
SJC28 was also higher for the failing subgroup (P = 0.027),
this difference in disease activity resulted from mainly
higher 12-month PGH scores of the failing patients
(P <0.0001) because DAS28(3v)-CRP calculation did
not reveal significant differences in the disease activity
between the two subcategories (P >0.05) (Figure 1B).
Higher PGH has an important role in excluding pa-
tients from Boolean remission creating higher disease
activity, and consequently Boolean remission has the ad-
vantage to exclude residual disease activity resulting from
high scores of PGH in the definition of remission.Table 4 EULAR response, low disease activity and
remission rates during TNF inhibitor treatment of the
rheumatoid arthritis cohort
3 months 6 months 12 months
Good response (%) 39.5 45.8 50.5
Moderate response (%) 49.5 39.8 31.9
Nonresponse (%) 14 14.4 17.6
DAS28(4v)-CRP <3.2 (%) 42.3 50.9 54.9
Low disease activity (%) 18.5 20.5 17.6
DAS28 remission 53 (23.9%) 65 (30.1%) 102 (37.4%)
Boolean remission 7 (3.2%) 23 (10.6%) 27 (9.9%)
EULAR, European League Against Rheumatism, TNF, tumour necrosis factor;
DAS28(4v)-CRP, disease activity score based on joints using four variables and
including C-reactive protein as the inflammatory marker; DAS28, disease
activity score based on 28 joints.Why do some of the DAS28 remission patients miss
Boolean remission?
We compared the 12-month disease activity of only
DAS28 remission patients and their Boolean remission
counterparts. In spite of the higher DAS28(4v)-CRP
values at 12 months for the only DAS28 remission group
(P <0.0001), there were no differences between DAS28
(3v)-CRP scores between the two categories (P = 0.26).
Higher PGH values were thereby also proved to con-
tribute to DAS28(4v)-CRP differences between remis-
sion categories (Figure 1C). These data suggest that
DAS28 remission criteria allow much greater residual
PGH-related disease activity for individuals being in
remission.Seropositivity and remission status
There was no difference in remission rates of rheuma-
toid factor or anti-cyclic citrullinated peptide positive/
negative patients according to either remission criteria;
however, DAS28 remission allowed more seropositive
and seronegative patients into remission than Boolean
criteria (P <0.05).Response to treatment
Clinical and laboratory data (TJC28, SJC28, PGH, CRP,
ESR, DAS28(4v)-CRP) showed significant sustained im-
provement during biological therapy in each remission
group from 3 to 12 months (all P <0.05), but nonremis-
sion patients showed poorer improvement of disease
activity during treatment. The majority of patients were
responders and response rates showed a shift from mo-
derate towards good response by 12 months, and the
low disease activity status similarly improved (Table 4).
Boolean remission patients more frequently showed good
response to therapy than DAS28 remission patients, but
most of the nonremission patients also reached at least
moderate response during TNFi therapy (Table 4). Both
DAS28 and Boolean remission statuses showed increasing
remission rates from 3 to 6 months, and then DAS28
remission further improved and Boolean remission stag-
nated (Table 4).Composite model for predicting Boolean remission versus
DAS28 remission statuses
Predictive factors for the different remission status were
investigated by binary logistic regression analysis, which
revealed that younger age and lower baseline TJC28 pre-
dict for both DAS28 and Boolean remission statuses
compared with nonremission. Younger age also predicts
Boolean remission versus only DAS28 remission at 12
months (Table 5).
Table 5 Binary logistic regression analysis for the prediction of different remission statuses
DAS28 remission versus nonremission Boolean remission versus nonremission Boolean versus only DAS28 remission
OR P value OR P value OR P value
Age 0.968 0.004 0.942 <0.0001 0.956 0.014
Baseline TJC28 0.946 0.018 0.910 0.031 – –
Analyses were controlled for baseline levels of disease activity components: C-reactive protein (mg/dl), tender joint count out of 28 joints (TJC28), swollen joint
count out of 28 joints, and patient global health. DAS28, disease activity score in 28 joints. P <0.05 indicates the association of the variable with different remission
statuses. Odds ratios (ORs) explain the probability of reaching different remission statuses with higher age and baseline TJC28.
Balogh et al. Arthritis Research & Therapy 2013, 15:R221 Page 6 of 8
http://arthritis-research.com/content/15/6/R221Discussion
Remission-orientated treatment is the principal target
either with disease-modifying antirheumatic drugs or
biological therapy in RA [18,19]. Several composite indi-
ces have been introduced to evaluate disease activity in
rheumatology practice (DAS28, SDAI, Clinical Disease
Activity Index) [20]. Increasing postulation for early
diagnosis and aggressive treatment has created a demand
for more stringent measures of response, especially re-
mission in disease development. In addition, it has been
suggested that it is possible to predict early response to
TNFi therapies using a mathematical model [21]. Previ-
ous remission criteria have been used in daily practice
and clinical trials, of which DAS28 remission criteria are
the most commonly used and reliable in clinical practice
[22]. The need for other stringent remission criteria cre-
ated a collaboration by ACR, EULAR and the Commit-
tee of Outcome Measures in Rheumatology Initiative
(OMERACT) group to work out the new ACR/EULAR
remission criteria in 2011 [11]. In this observational co-
hort we examined the frequency and sustainability of re-
mission according to the new criteria and the DAS28
(4v)-CRP-based criteria.
We followed a biologic-naive RA group being unrespon-
sive for different disease-modifying agents (disease-modi-
fying antirheumatic drugs), having high disease activity
and requiring the initiation of biological therapy. The ex-
amined patients were started on TNFi therapy that is
unique in terms of the homogenicity of the RA group. In-
vestigations were made in a clinical setting.
Boolean remission criteria allow fewer patients into re-
mission than DAS28(4v)-CRP criteria, and hence the
highest possible score for any subcriteria is ≤1; however,
DAS28 allows wide varieties also in TJC, SJC, CRP and
PGH. ACR/EULAR remission criteria are more stringent
in terms of allowing fewer patients into remission, and
in the view of these results fewer patients can reach this
requirement due to higher TJC28, SJC28, CRP or PGH
values at any timepoint. For the same reason, Boolean
remission patients were better responders on a group
basis than DAS28 remission patients. Recently de Punder
and colleagues found that anti-tumour necrosis factor-
treated patients who score 1 on every item of the ACR/
EULAR remission criteria had a DAS28(4v)-ESR higher(2.8) than the cutoff point for their DAS28(4v)-ESR re-
mission (<2.6) [23]. Hirabayashi and Ishii revealed that the
DAS28-ESR cutoff point necessary to predict remission
was <1.54 under the new criteria in clinical settings
for tocilizumab-treated patients; a DAS28-ESR cutoff
point <2.0 was previously examined as a candidate defi-
nition of remission by ACR/EULAR [11,24].
Several published reports have examined the effect of
PGH on ACR/EULAR criteria for clinical trials, and em-
phasise that missing the PGH criteria by ≤1 frequently
leaves patients in a nonremission status. Otherwise these
patients demonstrate a good clinical disease activity [12].
Similar observations were also confirmed in a solely clin-
ical setting of the ACR/EULAR criteria, neglecting CRP
from the definition of remission [6]. We present the first
PGH data on a biologic naive cohort starting TNFi treat-
ment. In patients missing Boolean remission due to one
subcriterion, PGH was found to be the strongest con-
tributory factor raising disease activity above the cutoff
in this cohort. In accordance with this, DAS28 remission
patients missing Boolean remission status have higher
post-treatment disease activity, primarily due to increased
PGH. Previous findings suggest that the assessment of
PGH may raise difficulties in defining remission in clinical
practice. Originally, the ACR/EULAR remission criteria
were developed for clinical trials. The literature reflects
that clinical trial conditions are different from routine
clinical practice and that patients may score PGH differ-
ently depending on their original disease activity [12].
Modification of PGH subcriteria to PGH ≤2 has been pro-
posed to allow more patients to reach ACR/EULAR re-
mission [25]. The limitation in clinical application of the
new remission criteria is that patients may score a high
PGH for reasons other than RA disease activity, raising
the opportunity for overtreatment; in contrast, minimisa-
tion of latent disease activity may ensure better long-term
radiographic outcomes.
We confirmed that despite remission rates being lower
in Boolean remission status, the majority of patients
gave at least moderate response to therapy and good re-
sponse improved from 3 to 12 months. One-fifth of our
patients presented low disease activity post treatment at
any timepoint and both the DAS28 and Boolean remis-
sion statuses improved from 3 to 12 months of therapy.
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hides inherent challenges as age, comorbidities and
nondisease-related factors may significantly influence
measurement of remission. In this study we confirmed
that younger age and lower baseline TJC28 were pre-
dictors for both DAS28 and Boolean remission status
compared with nonremission, which is consistent with
previous findings that gave impact for these predictors in
DAS28 remission [26]. Age has a further impact on remis-
sion status, younger patients being more likely to reach
Boolean remission compared with DAS28 remission,
which supports earlier aggressive treatment as it offers a
higher probability of sustained remission.
The drawbacks to our study are that calculations with
the Clinical Disease Activity Index and SDAI were not
calculated due to lack of data. We did not compare re-
mission criteria in the case of patients on solely disease-
modifying agents (disease-modifying antirheumatic drugs)
and we did not analyse according to different TNFi ther-
apies, although most studies to date have failed to show
differences in efficacy across the class. Our observational
study did not extend to data analysis on the predictive
value of remission criteria for further synovitis, bone
marrow oedema or radiographic progression. There is evi-
dence that a longer period in remission results in less
radiographic progression [10]. Additionally, several studies
confirm that subclinical disease activity, and possibly fur-
ther radiological progression, may be detectable despite
clinical remission, and applying stricter remission criteria
should guard against this happening [27]. Zhang and col-
leagues examined the radiologic and functional outcome
of RA patients 1 year after treatment initiation and found
that Boolean and SDAI/Clinical Disease Activity Index
definitions made better prediction for good outcomes than
DAS-based definitions [28]. Lillegraven and colleagues
first evaluated the relationship between the time in re-
mission and radiographic joint damage comparing ACR/
EULAR with DAS28-CRP-based remission on a clinical
observational RA cohort. Their findings suggest that the
Boolean-based definition has the highest, and the DAS28-
CRP-based definition has the lowest, likelihood ratio for
good radiographic outcome, therefore verifying the va-
lidity of new remission criteria in clinical settings [10].
Sakellariou and colleagues also confirmed the higher
probability of ultrasound-detected synovitis for DAS28 re-
mission than ACR/EULAR remission [29]. However, we
did not examine ultrasound/magnetic resonance imaging-
detected synovitis. Existing subclinical disease activity in
clinical remission establishes the demand for further
observational studies in the state of remission to in-
troduce new recommendations including imaging follow-
up strategies. Identifying predictors of remission will
help to achieve a better radiographic and functional
outcome [30].Conclusions
Remission remains the ideal therapeutic target. DAS28
criteria define the remission state allowing residual dis-
ease activity. High PGH scores do have an impact on de-
fining remission status using the new Boolean criteria.
The new criteria are more stringent in defining remis-
sion, suggesting they may lead to better long-term radio-
graphic outcomes. Patients at a younger age are more
likely to reach Boolean remission compared with DAS28
remission, emphasising the importance of early diagnosis
and appropriate treatment in RA. It will be interesting
to examine the utility of the new ACR/EULAR remis-
sion criteria in long-term follow-up studies focusing
on radiographic outcome.
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